Hepatoprotective Effect Of Epigallocatechin-Gallate (Egcg) And Sorafenib Against Den Induced Hepato Cellular Carcinoma In Experimental Animals

Background Hepatocellular carcinoma (HCC) arises from chronically inflamed and damaged liver tissue therefore, chemoprevention must be undertaken to reduce the incidence of HCC. Epigallocatechin gallate (EGCG) is a phytochemical, extracted from green tea. Past studies in animal models have revealed that it can suppress liver inflammation and fibrosis. Its role in HCC chemoprevention is not yet well established. Sorafenib is a chemotherapeutic agent, which significantly prolongs the survival of HCC patients with advanced-stage disease. The cost of sorafenib is very high, so combining this with EGCG can be cost-effective and as effective as sorafenib. Also to reduce the Side effects of Chemotherapeutic Drug. This study is aimed to assess the protective outcome of the phytochemical EGCG and chemotherapeutic drug Sorafenib in Hepatocellular carcinoma. Materials and methods Forty adult male Wistar albino rats of 3 months old were procured in this study. The rats were divided into 5 groups, 8 in each group. Group 1 has control rats and group 2 with negative control-treated only with Diethyl Nitrosamine (DEN). Group 3 is treated only with sorafenib and group 4 with EGCG alone and Group 5 received the combination of sorafenib and EGCG. After the probing period, the subjects were sacrificed and histopathological analysis was done. Alpha-fetoprotein level was measured by ELISA and liver enzymes were measured. Result Histopathological reports showed a satisfying decline in the degeneration and hyperchromatism among group 5 subjects. Alphafetoprotein level in group 5 was significantly lower than in group 2 and group 4 animals and it was statistically significant. Liver enzymes in group 5 were lower than in group 4 animals which indicate that group 5 subjects were doing better. We have found out that group 5 subjects had better antioxidant capacity when compared to group 2 and 3 animals. Conclusion We have reported that a combination ofsorafenib with EGCG has a comparable effect with standard-dose sorafenib. So we conclude that the combination of sorafenib and EGCG gives better chemoprotection and is effective against hepatocellular carcinoma.